Global Benign Prostatic Hyperplasia (BPH) Drugs Market Growth 2022-2028
As the global economy mends, the 2021 growth of Benign Prostatic Hyperplasia (BPH) Drugs will have significant change from previous year. According to our latest study, the global Benign Prostatic Hyperplasia (BPH) Drugs market size is USD million in 2022 from USD 3257.1 million in 2021, with a change of % between 2021 and 2022. The global Benign Prostatic Hyperplasia (BPH) Drugs market size will reach USD 4122.5 million in 2028, growing at a CAGR of 3.4% over the analysis period.
The United States Benign Prostatic Hyperplasia (BPH) Drugs market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Benign Prostatic Hyperplasia (BPH) Drugs market, reaching US$ million by the year 2028. As for the Europe Benign Prostatic Hyperplasia (BPH) Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Benign Prostatic Hyperplasia (BPH) Drugs players cover Eli Lilly, GlaxoSmithKline, Astellas Pharma, and Sanofi, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospitals
Drugstores
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Benign Prostatic Hyperplasia (BPH) Drugs by Country/Region, 2017, 2022 & 2028
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
2.2.1 Alpha-Blocker
2.2.2 Phosphodiesterase Type-5 Inhibitors
2.2.3 Others
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2022)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2017-2022)
2.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2017-2022)
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Drugstores
2.4.3 Others
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
2.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Market Share by Application (2017-2022)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Application (2017-2022)
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2017-2022)
3 Global Benign Prostatic Hyperplasia (BPH) Drugs by Company
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Company
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Company (2020-2022)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2022)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Company (2020-2022)
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2022)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2022)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company
3.4 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Location Distribution
3.4.2 Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region
4.1 World Historic Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Geographic Region (2017-2022)
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Geographic Region
4.2 World Historic Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country/Region (2017-2022)
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales by Country/Region (2017-2022)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue by Country/Region
4.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.4 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.5 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
4.6 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth
5 Americas
5.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country
5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022)
5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2022)
5.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
5.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2017-2022)
6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2017-2022)
6.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
6.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Country
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2022)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs by Country
8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022)
8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2022)
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
10.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
10.4 Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
11.3 Benign Prostatic Hyperplasia (BPH) Drugs Customer
12 World Forecast Review for Benign Prostatic Hyperplasia (BPH) Drugs by Geographic Region
12.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Forecast by Region
12.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Region (2023-2028)
12.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type
12.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Application
13 Key Players Analysis
13.1 Eli Lilly
13.1.1 Eli Lilly Company Information
13.1.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
13.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Eli Lilly Main Business Overview
13.1.5 Eli Lilly Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
13.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Astellas Pharma
13.3.1 Astellas Pharma Company Information
13.3.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
13.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Astellas Pharma Main Business Overview
13.3.5 Astellas Pharma Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
13.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
13.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Abbott
13.6.1 Abbott Company Information
13.6.2 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
13.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Abbott Main Business Overview
13.6.5 Abbott Latest Developments
13.7 Allergan
13.7.1 Allergan Company Information
13.7.2 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
13.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Allergan Main Business Overview
13.7.5 Allergan Latest Developments
13.8 TEVA
13.8.1 TEVA Company Information
13.8.2 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
13.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 TEVA Main Business Overview
13.8.5 TEVA Latest Developments
13.9 Mylan
13.9.1 Mylan Company Information
13.9.2 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
13.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Mylan Main Business Overview
13.9.5 Mylan Latest Developments
13.10 Novartis
13.10.1 Novartis Company Information
13.10.2 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
13.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Novartis Main Business Overview
13.10.5 Novartis Latest Developments
13.11 Merck
13.11.1 Merck Company Information
13.11.2 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
13.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Merck Main Business Overview
13.11.5 Merck Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Benign Prostatic Hyperplasia (BPH) Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Alpha-Blocker
Table 4. Major Players of Phosphodiesterase Type-5 Inhibitors
Table 5. Major Players of Others
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2022) & (M Units)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2022)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2017-2022) & ($ million)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2017-2022)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2017-2022) & (US$/Unit)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M Units)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2022)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2017-2022)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2017-2022)
Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2017-2022) & (US$/Unit)
Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2020-2022) & (M Units)
Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Company (2020-2022)
Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company (2020-2022)
Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Company (2020-2022) & (US$/Unit)
Table 21. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Producing Area Distribution and Sales Area
Table 22. Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
Table 23. Benign Prostatic Hyperplasia (BPH) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Geographic Region (2017-2022) & (M Units)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Geographic Region (2017-2022)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country/Region (2017-2022) & (M Units)
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country/Region (2017-2022)
Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022) & (M Units)
Table 35. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2017-2022)
Table 36. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2017-2022)
Table 38. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2022) & (M Units)
Table 39. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2022)
Table 40. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M Units)
Table 41. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2022)
Table 42. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2017-2022) & (M Units)
Table 43. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2017-2022)
Table 44. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2017-2022)
Table 46. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2022) & (M Units)
Table 47. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2022)
Table 48. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M Units)
Table 49. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2022)
Table 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022) & (M Units)
Table 51. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2017-2022)
Table 52. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2017-2022)
Table 54. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2022) & (M Units)
Table 55. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2022)
Table 56. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M Units)
Table 57. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022) & (M Units)
Table 59. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2022) & (M Units)
Table 63. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M Units)
Table 65. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Benign Prostatic Hyperplasia (BPH) Drugs
Table 67. Key Market Challenges & Risks of Benign Prostatic Hyperplasia (BPH) Drugs
Table 68. Key Industry Trends of Benign Prostatic Hyperplasia (BPH) Drugs
Table 69. Benign Prostatic Hyperplasia (BPH) Drugs Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 72. Benign Prostatic Hyperplasia (BPH) Drugs Customer List
Table 73. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2023-2028) & (M Units)
Table 74. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Forecast by Region
Table 75. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2023-2028) & (M Units)
Table 78. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Region (2023-2028) & (M Units)
Table 80. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2023-2028) & (M Units)
Table 82. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Country (2023-2028) & (M Units)
Table 84. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2023-2028) & (M Units)
Table 86. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2023-2028) & (M Units)
Table 90. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 93. Eli Lilly Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 95. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 96. Eli Lilly Main Business
Table 97. Eli Lilly Latest Developments
Table 98. GlaxoSmithKline Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 100. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 101. GlaxoSmithKline Main Business
Table 102. GlaxoSmithKline Latest Developments
Table 103. Astellas Pharma Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 105. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 106. Astellas Pharma Main Business
Table 107. Astellas Pharma Latest Developments
Table 108. Sanofi Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 110. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 111. Sanofi Main Business
Table 112. Sanofi Latest Developments
Table 113. Pfizer Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 115. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 116. Pfizer Main Business
Table 117. Pfizer Latest Developments
Table 118. Abbott Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 120. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 121. Abbott Main Business
Table 122. Abbott Latest Developments
Table 123. Allergan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 125. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 126. Allergan Main Business
Table 127. Allergan Latest Developments
Table 128. TEVA Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 130. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 131. TEVA Main Business
Table 132. TEVA Latest Developments
Table 133. Mylan Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 135. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 136. Mylan Main Business
Table 137. Mylan Latest Developments
Table 138. Novartis Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 140. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 141. Novartis Main Business
Table 142. Novartis Latest Developments
Table 143. Merck Basic Information, Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
Table 145. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 146. Merck Main Business
Table 147. Merck Latest Developments
List of Figures
Figure 1. Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 2. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate 2017-2028 (M Units)
Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Alpha-Blocker
Figure 10. Product Picture of Phosphodiesterase Type-5 Inhibitors
Figure 11. Product Picture of Others
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2021
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2017-2022)
Figure 14. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Hospitals
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Hospitals (2017-2022) & (M Units)
Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Drugstores
Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Drugstores (2017-2022) & (M Units)
Figure 18. Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Others
Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Others (2017-2022) & (M Units)
Figure 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2022)
Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application in 2021
Figure 22. Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market by Company in 2021 ($ Million)
Figure 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Company in 2021
Figure 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Geographic Region (2017-2022)
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Geographic Region in 2021
Figure 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2017-2022)
Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country/Region in 2021
Figure 28. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales 2017-2022 (M Units)
Figure 29. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2017-2022 ($ Millions)
Figure 30. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales 2017-2022 (M Units)
Figure 31. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2017-2022 ($ Millions)
Figure 32. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales 2017-2022 (M Units)
Figure 33. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2017-2022 ($ Millions)
Figure 34. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales 2017-2022 (M Units)
Figure 35. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2017-2022 ($ Millions)
Figure 36. Americas Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2021
Figure 37. Americas Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2021
Figure 38. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 39. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 40. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 41. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 42. APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2021
Figure 43. APAC Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Regions in 2021
Figure 44. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 45. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 46. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 47. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 48. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 49. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 50. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2021
Figure 51. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2021
Figure 52. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 53. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 54. UK Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 55. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 56. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 57. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country in 2021
Figure 58. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country in 2021
Figure 59. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 60. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 61. Israel Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 62. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 63. GCC Country Benign Prostatic Hyperplasia (BPH) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 64. Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in 2021
Figure 65. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 66. Industry Chain Structure of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 67. Channels of Distribution
Figure 68. Distributors Profiles
